44,626 Shares in GSK PLC Sponsored ADR $GSK Bought by FCG Investment Co

Key Points

• FCG Investment Co has acquired a new position in GSK PLC by purchasing 44,626 shares valued at approximately $1.73 million, representing 1.1% of its portfolio.
• GSK recently beat analysts' earnings estimates for the quarter, reporting $1.23 earnings per share compared to the expected $1.12 and achieving a revenue of $10.64 billion.
• Despite the strong earnings, GSK has announced a dividend cut, with an upcoming quarterly dividend of $0.4206, reflecting a 4.3% yield, and a payout ratio of 79.17%.

FCG Investment Co acquired a new stake in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 44,626 shares of the pharmaceutical company's stock, valued at approximately $1,729,000. GSK comprises approximately 1.1% of FCG Investment Co's portfolio, making the stock its 27th biggest holding.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. HHM Wealth Advisors LLC grew its holdings in shares of GSK by 222.2% during the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock worth $26,000 after purchasing an additional 460 shares during the period. Costello Asset Management INC purchased a new stake in shares of GSK during the 1st quarter worth about $31,000. Richardson Financial Services Inc. grew its holdings in shares of GSK by 127.9% during the 1st quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock worth $33,000 after purchasing an additional 472 shares during the period. Olde Wealth Management LLC purchased a new stake in shares of GSK during the 1st quarter worth about $36,000. Finally, Cary Street Partners Investment Advisory LLC grew its holdings in shares of GSK by 525.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company's stock worth $39,000 after purchasing an additional 852 shares during the period. Institutional investors and hedge funds own 15.74% of the company's stock.

Analysts Set New Price Targets

GSK has been the subject of a number of research reports. Wall Street Zen upgraded GSK from a "hold" rating to a "buy" rating in a report on Sunday, August 3rd. Berenberg Bank reiterated a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Finally, Hsbc Global Res upgraded GSK to a "strong sell" rating in a report on Monday, April 28th. Seven analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Reduce" and an average target price of $37.38.

GSK Stock Down 0.1%

Shares of GSK stock traded down $0.0250 on Thursday, hitting $40.0450. 2,140,001 shares of the company's stock traded hands, compared to its average volume of 5,172,006. The stock has a market cap of $81.60 billion, a P/E ratio of 18.54, a PEG ratio of 1.72 and a beta of 0.51. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07. The firm's 50-day moving average is $38.40 and its 200 day moving average is $38.04. GSK PLC Sponsored ADR has a 52-week low of $31.72 and a 52-week high of $44.67.

GSK (NYSE:GSK - Get Free Report) last released its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.12 by $0.11. GSK had a return on equity of 49.22% and a net margin of 10.81%.The company had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $7.92 billion. During the same period in the prior year, the business posted $0.43 EPS. The business's revenue was up 1.3% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Equities analysts anticipate that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be paid a dividend of $0.4206 per share. The ex-dividend date is Friday, August 15th. This represents a $1.68 annualized dividend and a yield of 4.2%. GSK's dividend payout ratio (DPR) is 77.78%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.